NGAL (neutrophil gelatinase-associated lipocalin) is a novel biomarker for diagnosing acute kidney injury (AKI). Its measurement can detect damage within 2 hrs of occurrence and also shows a proportionate response to injury. This enables the physician to make crucial decisions regarding treatment and withdrawal of nephrotoxic drugs, before kidney damage evolves into a potentially fatal kidney failure.
Other renal status markers such as serum creatinine take two to three days to identify kidney damage. NGAL determination permits the early diagnosis and prognostic stratification of acute kidney injury.
The NGAL Test™ from BioPorto is based on the principle of turbidimetry, used in a wide range of automated clinical chemistry analysers. The NGAL Test™ is exclusively available in the UK from Alpha Laboratories who have been actively supporting clinical education in the adoption of this marker, to benefit patients.
BioPorto is now also partnering with analyser suppliers such as Siemens Healthcare Diagnostics and Roche Diagnostics, to further promote use of The NGAL Test™ and its routine adoption in clinical laboratories. However, distribution remains through BioPorto's existing sales channels and Alpha Laboratories should be contacted for further product information or trials.
